Learn, Analyse & Invest
only with
only with
+91
Download Orca
Sanjivani Paranteral Ltd.
Sanjivani Paranteral
Sanjivani Paranteral Ltd. live price is ₹ 0.00. Price change 0.00, 0.00 percent.
₹ 0.00
0.00 (0.00)%
Healthcare
Small-cap - With a market cap of ₹2.21 Cr.
| EX-Date | Purpose |
|---|---|
| 25 05 2021 | Quarterly Results & Audited Results |
| 25 06 2021 | Preferential Issue of shares |
| 26 07 2021 | Quarterly Results |
| 12 11 2021 | Quarterly Results |
| 14 02 2022 | Quarterly Results |
| 17 05 2022 | Audited Results |
| 08 08 2022 | Quarterly Results |
| 14 11 2022 | Quarterly Results |
| 14 02 2023 | Quarterly Results |
| 06 05 2023 | Audited Results |
| 24 07 2023 | Quarterly Results |
| 18 10 2023 | Quarterly Results |
| 25 12 2023 | Preferential Issue of shares & Issue Of Warrants |
| 05 02 2024 | Quarterly Results |
| 08 04 2024 | Inter alia, to consider and transact the following businesses: 1. To consider the proposal for Change in Designation of Mr. Srivardhan Ashwani Khemka (DIN: 08942106), from Non-Executive Director to Executive Director with effect from 08th April, 2024; 2. To take a note of Resignation of Mr. Shrenikkumar Parasmalji Solanki, Independent Director of the Company with effect from 08th April, 2024; 3. Appointment of Mr. Abhay Shah (DIN: 10562812) as an Additional Director of the company under Independent Category with effect from Monday, 08th April, 2024, till ensuing General Meeting. 4. Any other matter with the permission of Chair and with the consent of a majority of the Directors present in the Meeting including include at least one Independent Director. |
| 28 10 2024 | Quarterly Results |
| 10 02 2025 | Quarterly Results |
| 27 05 2025 | Dividend & Audited Results |
| 12 08 2025 | Quarterly Results |
| 14 11 2025 | Quarterly Results |
| 13 02 2026 | Quarterly Results |
| 14 05 2026 | Quarterly Results & Audited Results |
| 21 05 2026 | Preferential Issue of shares |
| 23 07 2026 | Preferential Issue of shares & 1. To consider and discuss the proposal for raising funds by way of issuance of warrants or other convertible securities through one or more permissible modes, including but not limited to a Preferential Issue, Rights Issue, or any other method as may be determined by the Board, subject to such regulatory, statutory, and other approvals as may be required, including the approval of the shareholders of the Company for this purpose; 2. Any other matter with the permission of Chair and with the consent of a majority of the Directors present in the Meeting including at least one Independent Director. |
| 14 08 2026 | Quarterly Results & A.G.M. |